|
Variate
|
OS
|
PFS
|
|---|
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
|---|
|
Age
|
1.38
|
1.69–9.40
|
< 0.01
|
0.39
|
0.87–2.51
|
0.15
|
|
Clinical stage
|
− 0.39
|
0.22–2.06
|
0.57
|
0.69
|
1.23–3.23
|
0.01
|
|
B symptoms
|
− 0.93
|
0.12–1.35
|
0.63
|
0.45
|
0.97–2.56
|
0.07
|
|
Spleen involvement
|
− 0.05
|
0.24–3.87
|
0.95
|
0.34
|
0.74–2.67
|
0.30
|
|
IPI
|
1.01
|
0.59–12.70
|
0.20
|
0.02
|
0.51–2.04
|
0.96
|
|
LDH
|
0.29
|
0.49–3.67
|
0.57
|
0.24
|
0.76–2.15
|
0.35
|
|
β2-MG
|
0.02
|
0.33–3.18
|
0.98
|
–
| | |
|
Rituximab
|
− 0.13
|
0.34–2.26
|
0.80
|
–
| | |
|
CR after first-line chemotherapy
|
− 1.54
|
0.09–0.49
|
< 0.01
|
− 0.24
|
0.48–1.27
|
0.33
|
|
PD-L1 expression in tumor cells
|
1.40
|
1.61–10.23
|
< 0.01
|
0.46
|
1.00–2.51
|
0.05
|
-
IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death ligand 1, – not included
